Novel CCR5 antagonists for the treatment of HIV infection: A review of compounds patented in 2006 2008

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 3, 2010, Pages 325-354

  Yang, Hanbiao ^a   Rotstein, David M ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Aplaviroc; CCR5; Entry inhibitors; HIV 1; Maraviroc; TAK 779; Vicriviroc

Indexed keywords

ANTIRETROVIRUS AGENT; APLAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GW 871340; HYDANTOIN; IMIDAZOLE DERIVATIVE; IMIDAZOPIPERIDINE; INCB 9471; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PF 232798; PIPERIDINE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VICRIVIROC; WO 2006001751;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG BINDING; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAXIMUM PLASMA CONCENTRATION; PATENT; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT INDICATION; VIRUS CELL TRANSFORMATION; VIRUS REPLICATION;

AIDS VACCINES; ANTI-HIV AGENTS; CYCLOHEXANES; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; PATENTS AS TOPIC; RECEPTORS, CCR5; TRIAZOLES;

EID: 77649172681     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903575674     Document Type: Review

References (86)

1. Available from: http://www.who.int/hiv/data/ 2008-global-summary-AIDS-ep. png
2. Perks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009. [Epub ahead of print]
3. Melby T, Westby M. Inhibitors of viral entry. Handb Exp Pharmacol 2009;189:177-202
4. Leonard JT, Roy K. The HIV entry inhibitors revisited. Curr Med Chem 2006;13(8):911-934
5. Pierson TC, Doms RW, Poehlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004;14(4):255-270
6. Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol 2004;36(1):35-38
7. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1.alpha., and MIP-1.beta. as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270(5243):1811-1815
8. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381(6584):661-666
9. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structure gene. Science 1996;273(5283):1856-1862
10. Dorr P, Perros M. CCR5 inhibitors in HIV-1 therapy. Expert Opin Drug Discov 2008;3(11):1345-1361
11. Repik A, Richards KH, Clapham PR. The promise of CCR5 antagonists as new therapies for HIV-1. Curr Opin Invest Drugs 2007;8(2):130-139
12. Barber CG. CCR5 antagonists for the treatment of HIV. Curr Opin Invest Drugs 2004;5(8):851-861
13. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Nat Acad Sci USA 1999;96(10):5698-5703
14. Hale JJ, Budhu RJ, Mills SG, et al. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg Med Chem Lett 2001;11(11):1437-1440
15. Hale JJ, Budhu RJ, Holson, et al. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent Anti-HIV activity. Bioorg Med Chem Lett 2001;11(20):2741-2745
16. Hale JJ, Budhu RJ, Mills SG, et al. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity. Bioorg Med Chem Lett 2002;12(20):2997-3000
17. Lynch CL, Hale JJ, Budhu RJ, et al. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV. Bioorg Med Chem Lett 2002;12(20):3001-3004
18. Lynch CL, Willoughby CA, Hale JJ, et al. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains. Bioorg Med Chem Lett 2003;13(1):119-123
19. Willoughby CA, Rosauer KG, Hale JJ, et al. 1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains. Bioorg Med Chem Lett 2003;13(3):427-431
20. Kim D, Wang L, Hale JJ, et al. Design, antiviral and pharmacokinetic profiles of potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists for the treatment of HIV-1 infection. Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003, MEDI-162
21. Kim D, Wang L, Hale JJ, et al. Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties. Bioorg Med Chem Lett 2005;15(8):2129-2134
22. Cohen C, DeJesus E, Mills A, et al. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days monotherapy. Sydney, Australia: 4th IAS Conferences on AIDS Pathogenesis, Treatment and Prevention, July 22-25, 2007
23. Available from: http://www.incyte.com/drugs-product-pipeline.html
24. Ness TL, Kunkel SL, Hogaboam CM. CCR5 antagonists: the answer to inflammatory disease? Expert Opin Ther Pat 2006;16(8):1051-1065
25. Kuritzkes D, Kar S, Kirkpatrick P. Maraviroc. Nat Rev Drug Disc 2008;7(1):15-16
26. Sayana S, Khanlou H. Maraviroc: a new CCR5 antagonist. Expert Rev Anti Infect Ther 2008;7(1):9-19
27. Dorr P, Westby M, McFadyen L, et al. PF-232798, a second generation oral CCR5 antagonist. 15th Conference on Retroviruses and Opportunistic Infections, 3-6 February 2008, Boston, MA. Abstract 737
28. Pfizer. 8-Azabicyclo[3.2.1]octane derivatives with an activity on chemokine CCR5 receptors and their preparation, pharmaceutical compositions and use for treatment of inflammatory diseases and infection caused by HIV and genetically related retroviruses. WO2006067584; 2006
29. Pfizer. Preparation of 1,4¢-bipiperidinyl carboxamide derivatives as chemokine CCR5 receptor antagonists. WO2006077499; 2006
30. Tagat JR, McCombie SW, Nazareno D, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1 (R)-4-(trifluoromethyl)phenyl}ethyl-3(S) - methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004;47:2405-2408
31. Pfizer. Preparation of triazolylpiperidine derivatives for use as CCR5 receptor modulators for treating various diseases. WO2006136917; 2006
32. Pfizer. Piperidine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as modulators of chemokine CCR5 receptors. WO2007066201; 2007
33. Barber CG, Fenwick DR, Pryde DC, Stephenson PT. Preparation of piperidine derivatives as modulators, especially antagonists, of chemokine CCR5 receptors. WO2007116313; 2007
34. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005;49(12):4911-4919
35. Schering Plough. Piperazine derivatives and their preparation, pharmaceutical compositions and use as CCR5 antagonists for treatment of human immunodeficiency virus or inflammatory diseases. US2006105964; 2006
36. Schering Corp. Preparation of piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors. WO2006091692; 2006
37. Schering Corp. Piperidinylpiperidine derivatives useful as inhibitors of chemokine receptors and their preparation and pharmaceutical compositions; 2006. CODEN: PIXXD2 WO 2006091534 A1 20060831 CAN 145:293046 AN 2006:885318 CAPLUS
38. Schering Corp. CCR5 antagonists useful for treating HIV. US2007203149; 2007
39. Schering Corp. Synthesis of CCR5 receptor antagonists. WO2006074270; 2006
40. Schering Corp. Preparation of 4-substituted piperidinyl derivatives as intermediates for synthesizing CCR-5 receptor antagonists. WO2008079284; 2008
41. Schering Corp. Preparation of pharmaceutical salts of piperazine compounds. WO2006074269; 2006
42. Ono Pharmaceutical. Preparation of N-containing heterocyclic compounds as CCR5 antagonists. WO2006030925; 2006
43. Ono Pharmaceutical. Preparation of nitrogenated heterocyclic derivatives as antagonists of chemokine receptor 5 (CCR5). WO2007105637; 2007
44. AstraZeneca. Preparation of piperidine derivatives as CCR5 modulators. WO2006001751; 2006
45. AstraZeneca. Preparation of piperidine and 8-azabicyclo[3.2.1]octane derivatives as modulators of chemokine receptor CCR5. WO2006001752; 2006
46. AstraZeneca. Process for the preparation of N-(4-piperidinyl)- Nethylphenylacetamides from N-Boc-4-oxopiperidine. WO2006064221; 2006
47. AstraZeneca. Preparation of 4-[3-(1,1-difluoroethyl)-5- methyl-4H-1,2,4-triazol-4-yl]-1- {(1R,3R)-3-(3,5-difluorophenyl)- 1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine for the treatment of CCR5 disease. US2008139612; 2008
48. Astrazeneca. Preparation of 4-{(1R,3R)-1-(3,5- difluorophenyl)-3-[4-(3- ethyl- 5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl] butyl}-1- (methylsulfonyl)piperidine for use in the treatment of CCR5 mediated diseases. US2008139613; 2008
49. Roche. Preparation of 1-oxa-3,9-diazaspiro[5.5]undecan-2-ones and 1-oxa-3,8-diazasprio[4.5]decan-2-ones as CCR5 receptor antagonists for treating inflammatory and infectious diseases. US2005176703; 2005
50. Rotstein DM, Gabriel SD, Makra F, et al. Spiropiperidine CCR5 antagonists. Bioorg Med Chem Lett 2009;19(18):5401
51. Roche. Heterocyclic derivatives as CCR5 receptor ligands and their preparation, pharmaceutical compositions and use in the treatment of viral infections. WO2008119663; 2008
52. Roche. Preparation of heterocyclic antiviral compounds, particularly (3-hexahydropyrrolo[3,4-c] pyrrol-2-yl)-1-phenylpropylamine and [3-(hexahydropyrrolo[3,4-c] pyrrol-2-yl)propyl]phenylamine derivatives as antagonists of chemokine CCR5 receptor, useful for treating HIV and genetically related retroviral infections. WO2005121145; 2005
53. Roche. Preparation of 3,7-diazabicyclo[3.3.0]octane CCR5 chemokine receptor antagonists useful as antiaids drugs. US2007191335; 2007
54. Roche. Preparation of 3,7-diazabicyclo[3.3.0]octane compounds as antiviral agents. WO2007093515; 2007
55. Roche. Pyrrolo[3,4-c]pyrrole derivatives as heterocyclic antiviral compounds and CCR5 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of HIV infection, AIDS and ARC. US2007191406; 2007
56. Roche. Octahydropyrrolo[3,4-c]pyrrole derivatives as antiviral agents and their preparation, pharmaceutical compositions and use in the treatment of HIV infection. WO2008034731; 2008
57. GSK. Preparation of pyrrolidine and azetidine compounds as CCR5 antagonists. WO2004055016; 2004
58. ViroChem Pharma. Preparation of spirohydantoins for the modulation of chemokine receptor activity. WO2006000096; 2006
59. ViroChem Pharma. Preparation of spirotropane compounds and methods for the modulation of chemokine receptor activity to block cellular entry of HIV. WO2006060918; 2006
60. ViroChem Pharma. Preparation of spirotropane compounds and therapeutic use as modulators of chemokine receptor activity. WO2006060919; 2006
61. ViroChem Pharma. Preparation of novel spiropiperidine compounds for the modulation of chemokine receptor activity. WO2007065256; 2007
62. ViroChem Pharma. Spirotropane compounds, processes for preparing them, pharmaceutical compositions containing them, and their use as modulators of CCR5 chemokine receptors. WO2007143847; 2007
63. AnorMed Inc. Preparation of piperidinyl substituted ureas and amides as chemokine receptor binding compounds. WO2006138350; 2006
64. AnorMed Inc. Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus. WO2007022371; 2007
65. Genzyme Corp. Preparation of piperidine derivatives as modulators of chemokine receptor in particular CCR5 receptor. WO2008070758; 2008
66. Kemia. Preparation of aryl bicyclo and spiro compounds as therapeutic modulators of CCR-5 activity. WO2006130426; 2006
67. Ernst J, Dahl R, Lum C, et al. Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists. Bioorg Med Chem Lett 2008;18(4):1498-1501
68. Yang H, Lin X-F, Padilla F, et al. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undecan-2-one CCR5 antagonist. Bioorg Med Chem Lett 2009;19(1):209-213
69. Auspex Pharmaceuticals. 8-Azabicyclo[3.2.1]octane-base compounds, preparation and utility of CCR5 inhibitors and use in the treatment of infections. US2008146605; 2008
70. Concert Pharmaceuticals. Preparation of deuterated triazolyl tropane derivatives as CCR5 receptor inhibitors. WO2008063600; 2008
71. Benson SW. The C-D bond strength is considered to be 0.9 kcal greater than that of C-H: foundations of chemical kinetics. Mc-Graw-Hill Book Co., Inc.: New York; 1960. p. 676
72. Long Y, Song Y, Jiang X. Shanghai Institute of Materia Medica. Preparation of 4-(piperazin-1-yl)-piperidine derivatives as chemokine receptor inhibitors for treatment of AIDS. CN1789263; 2006
73. Shanghai Target Drug Corp. Preparation of piperidine derivatives as CCR5 antagonists for treatment of AIDS. CN1939916; 2007
74. Ma D, Yu S, Li B, et al. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ChemMedChem 2007;2(2):187-193
75. Price DA, Armour D, De Groot M, et al. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 2006;16(17):4633-4637
76. Pearlstein R, Vaz R, Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ preparation and utility of CCR5 inhibitors and use in the treatment of infections. US2008146605; 2008
77. Concert Pharmaceuticals. Preparation of deuterated triazolyl tropane derivatives as CCR5 receptor inhibitors. WO2008063600; 2008
78. Benson SW. The C-D bond strength is considered to be 0.9 kcal greater than that of C-H: foundations of chemical kinetics. Mc-Graw-Hill Book Co., Inc.: New York; 1960. p. 676
79. Long Y, Song Y, Jiang X. Shanghai Institute of Materia Medica. Preparation of 4-(piperazin-1-yl)-piperidine derivatives as chemokine receptor inhibitors for treatment of AIDS. CN1789263; 2006
80. Shanghai Target Drug Corp. Preparation of piperidine derivatives as CCR5 antagonists for treatment of AIDS. CN1939916; 2007
81. Ma D, Yu S, Li B, et al. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ChemMedChem 2007;2(2):187-193
82. Price DA, Armour D, De Groot M, et al. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 2006;16(17):4633-4637
83. Pearlstein R, Vaz R, Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 2003;46(11):2017-2022
84. Kim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008;197:262-265
85. Dummond JB, Paterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acuir Immune Defic Syndr 2009;51(5):546-553
86. Ness TL, Kunkel SL, Hogaboam CM. CCR5 antagonists: the answer to inflammatory disease? Expert Opin Ther Pat 2006;16(8):1051-1065